---
figid: PMC8041604__CMAR-13-3081-g0004
figtitle: Mechanisms of PI3K/Akt/mTOR pathway and MAPK pathway, and inhibitors in
  ovarian cancer clinical development
organisms:
- Homo sapiens
- Mus musculus
- Adenoviridae
- Amaranthus caudatus
- NA
pmcid: PMC8041604
filename: CMAR-13-3081-g0004.jpg
figlink: pmc/articles/PMC8041604/figure/f0004/
number: F4
caption: The mechanisms of PI3K/Akt/mTOR pathway and MAPK pathway, and inhibitors
  in ovarian cancer clinical development. Illustration the therapy strategy via inhibiting
  the PI3K/Akt/mTOR pathway (green) and MAPK pathway (amaranth) in ovarian cancer
  patients with PIK3CA and KRAS gene mutation. The orange represents a different inhibitory
  effect of repressing tumor growth by targeting different sites on the PI3K/Akt/mTOR
  pathway. For patients with PIK3CA gene mutation, clinical treatment drugs are mainly
  divided into PI3K inhibitor, AKT inhibitor, and mTOR inhibitor. The blue represents
  a different inhibitor target MAPK pathway in ovarian cancer patients with KRAS gene
  mutation. The therapy strategy includes restricting KRAS bound to GTP and targeting
  its downstream signaling pathway.
papertitle: Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets
  in Ovarian Cancer.
reftext: Tao Guo, et al. Cancer Manag Res. 2021;13:3081-3100.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9553059
figid_alias: PMC8041604__F4
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC8041604__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8041604__CMAR-13-3081-g0004.html
  '@type': Dataset
  description: The mechanisms of PI3K/Akt/mTOR pathway and MAPK pathway, and inhibitors
    in ovarian cancer clinical development. Illustration the therapy strategy via
    inhibiting the PI3K/Akt/mTOR pathway (green) and MAPK pathway (amaranth) in ovarian
    cancer patients with PIK3CA and KRAS gene mutation. The orange represents a different
    inhibitory effect of repressing tumor growth by targeting different sites on the
    PI3K/Akt/mTOR pathway. For patients with PIK3CA gene mutation, clinical treatment
    drugs are mainly divided into PI3K inhibitor, AKT inhibitor, and mTOR inhibitor.
    The blue represents a different inhibitor target MAPK pathway in ovarian cancer
    patients with KRAS gene mutation. The therapy strategy includes restricting KRAS
    bound to GTP and targeting its downstream signaling pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pik3r1
  - Pik3ca
  - ras
  - Hras
  - Kras
  - Rem1
  - Otp
  - Rasa1
  - Pten
  - Map2k1
  - Akt1
  - Ralgds
  - Rin1
  - Tiam1
  - Map2k2
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - Mdk
  - Rala
  - Cdkn1b
  - Dctn6
  - Psmd9
  - Mtor
  - Abl1
  - Ccdc88a
  - Trp53
  - Mdm2
  - Bad
  - Rac1
  - Cdc42
  - Tbc1d4
  - Gsk3b
  - Bcl2l11
  - gs
  - Gs
  - Bcl2
  - Eif4ebp1
  - Pdcd4
  - Epha4
  - Map2k4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTG1
  - KRAS
  - HRAS
  - NRAS
  - OTP
  - RASA1
  - PTEN
  - MAP2K1
  - AKT1
  - AKT2
  - AKT3
  - RALGDS
  - RIN1
  - TIAM1
  - MAP2K2
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - MAP2K7
  - RALA
  - RALB
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - MTOR
  - ABL1
  - MTTP
  - DSP-AS1
  - ABL2
  - CCDC88A
  - TP53
  - TP63
  - TP73
  - MDM2
  - BAD
  - GPLD1
  - PLD1
  - PLD2
  - PLD3
  - PLD4
  - PLD5
  - PLD6
  - RAC1
  - RNASE1
  - CDC42
  - TBC1D4
  - GSK3A
  - GSK3B
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - ETS1
  - ETS2
  - BCL2L11
  - GNAS
  - GNAL
  - BCL2
  - EIF4EBP1
  - PDCD4
  - MAP2K4
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ARS853
  - ODP
  - GDC0941
  - OTP
  - Selumetinib
  - AZD6244
  - BEZ235
  - ATP
  - Citrate
  - Rapamycin
  - AZD5483
  - Glucose
  - GS
---
